345 related articles for article (PubMed ID: 34075637)
41. Adapted Immune Responses of Myeloid-Derived Cells in Fatty Liver Disease.
Hundertmark J; Krenkel O; Tacke F
Front Immunol; 2018; 9():2418. PubMed ID: 30405618
[TBL] [Abstract][Full Text] [Related]
42. Myeloid-Derived Suppressor Cells in Colorectal Cancer.
Sieminska I; Baran J
Front Immunol; 2020; 11():1526. PubMed ID: 32849517
[TBL] [Abstract][Full Text] [Related]
43. A Call for Epidemiological Research on Myeloid-Derived Suppressor Cells in Ovarian Cancer: A Review of the Existing Immunological Evidence and Suggestions for Moving Forward.
Stenzel AE; Abrams SI; Moysich KB
Front Immunol; 2019; 10():1608. PubMed ID: 31354741
[TBL] [Abstract][Full Text] [Related]
44. Lipid Metabolism in Tumor-Associated Myeloid-Derived Suppressor Cells.
Liu W; Song H; Li X; Ren D; Ding S; Li Y
Adv Exp Med Biol; 2021; 1316():103-115. PubMed ID: 33740246
[TBL] [Abstract][Full Text] [Related]
45. Myeloid derived-suppressor cells: their role in cancer and obesity.
Ostrand-Rosenberg S
Curr Opin Immunol; 2018 Apr; 51():68-75. PubMed ID: 29544121
[TBL] [Abstract][Full Text] [Related]
46. Deciphering the Crosstalk Between Myeloid-Derived Suppressor Cells and Regulatory T Cells in Pancreatic Ductal Adenocarcinoma.
Siret C; Collignon A; Silvy F; Robert S; Cheyrol T; André P; Rigot V; Iovanna J; van de Pavert S; Lombardo D; Mas E; Martirosyan A
Front Immunol; 2019; 10():3070. PubMed ID: 32038621
[TBL] [Abstract][Full Text] [Related]
47. Circulating CD14(+) HLA-DR(-/low) myeloid-derived suppressor cells in leukemia patients with allogeneic hematopoietic stem cell transplantation: novel clinical potential strategies for the prevention and cellular therapy of graft-versus-host disease.
Yin J; Wang C; Huang M; Mao X; Zhou J; Zhang Y
Cancer Med; 2016 Jul; 5(7):1654-69. PubMed ID: 27109254
[TBL] [Abstract][Full Text] [Related]
48. Regulating Histone Deacetylase Signaling Pathways of Myeloid-Derived Suppressor Cells Enhanced T Cell-Based Immunotherapy.
Adeshakin AO; Adeshakin FO; Yan D; Wan X
Front Immunol; 2022; 13():781660. PubMed ID: 35140716
[TBL] [Abstract][Full Text] [Related]
49. Immunotherapy Targeting Myeloid-Derived Suppressor Cells (MDSCs) in Tumor Microenvironment.
Gao X; Sui H; Zhao S; Gao X; Su Y; Qu P
Front Immunol; 2020; 11():585214. PubMed ID: 33613512
[TBL] [Abstract][Full Text] [Related]
50. Early Activation of Myeloid-Derived Suppressor Cells Participate in Sepsis-Induced Immune Suppression via PD-L1/PD-1 Axis.
Ruan WS; Feng MX; Xu J; Xu YG; Song CY; Lin LY; Li L; Lu YQ
Front Immunol; 2020; 11():1299. PubMed ID: 32719675
[No Abstract] [Full Text] [Related]
51. Myeloid-Derived Suppressor Cells Mediate T Cell Dysfunction in Nonhuman Primate TB Granulomas.
Singh B; Singh DK; Ganatra SR; Escobedo RA; Khader S; Schlesinger LS; Kaushal D; Mehra S
mBio; 2021 Dec; 12(6):e0318921. PubMed ID: 34903057
[TBL] [Abstract][Full Text] [Related]
52. The Emerging Role of Myeloid-Derived Suppressor Cells in the Glioma Immune Suppressive Microenvironment.
Mi Y; Guo N; Luan J; Cheng J; Hu Z; Jiang P; Jin W; Gao X
Front Immunol; 2020; 11():737. PubMed ID: 32391020
[TBL] [Abstract][Full Text] [Related]
53. The immunobiology of myeloid-derived suppressor cells in cancer.
Motallebnezhad M; Jadidi-Niaragh F; Qamsari ES; Bagheri S; Gharibi T; Yousefi M
Tumour Biol; 2016 Feb; 37(2):1387-406. PubMed ID: 26611648
[TBL] [Abstract][Full Text] [Related]
54. Myeloid-Derived Suppressor Cells: Ductile Targets in Disease.
Consonni FM; Porta C; Marino A; Pandolfo C; Mola S; Bleve A; Sica A
Front Immunol; 2019; 10():949. PubMed ID: 31130949
[TBL] [Abstract][Full Text] [Related]
55. Targeting myeloid-derived suppressive cells in the tumor microenvironment to enhance the efficacy of cancer immunotherapy.
Huo S; Liu L; Li Q; Wang J
Discov Med; 2020; 30(161):119-128. PubMed ID: 33593480
[TBL] [Abstract][Full Text] [Related]
56. The Role of Myeloid-Derived Suppressor Cells (MDSCs) in the Development and/or Progression of Endometriosis-State of the Art.
Suszczyk D; Skiba W; Jakubowicz-Gil J; Kotarski J; Wertel I
Cells; 2021 Mar; 10(3):. PubMed ID: 33803806
[TBL] [Abstract][Full Text] [Related]
57. Circulating myeloid-derived suppressor cells: An independent prognostic factor in patients with breast cancer.
Safarzadeh E; Hashemzadeh S; Duijf PHG; Mansoori B; Khaze V; Mohammadi A; Kazemi T; Yousefi M; Asadi M; Mohammadi H; Babaie F; Baradaran B
J Cell Physiol; 2019 Apr; 234(4):3515-3525. PubMed ID: 30362521
[TBL] [Abstract][Full Text] [Related]
58. Receptor Tyrosine Kinase Inhibitor Sunitinib as Novel Immunotherapy to Inhibit Myeloid-Derived Suppressor Cells for Treatment of Endometriosis.
He Y; Hung SW; Liang B; Zhang R; Gao Y; Chu CY; Zhang T; Xu H; Chung JPW; Wang CC
Front Immunol; 2021; 12():641206. PubMed ID: 34367125
[TBL] [Abstract][Full Text] [Related]
59. Granulocytic Myeloid-Derived Suppressor Cells as Negative Regulators of Anticancer Immunity.
Kramer ED; Abrams SI
Front Immunol; 2020; 11():1963. PubMed ID: 32983128
[TBL] [Abstract][Full Text] [Related]
60. Explicating the Pivotal Pathogenic, Diagnostic, and Therapeutic Biomarker Potentials of Myeloid-Derived Suppressor Cells in Glioblastoma.
Richard SA
Dis Markers; 2020; 2020():8844313. PubMed ID: 33204365
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
